A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Status:	Recruiting
Conditions:	Dermatology
Therapuetic Areas:	Dermatology / Plastic Surgery
Healthy:	No
Age Range:	18 - 65
Updated:	4/3/2019
Start Date:	November 26, 2018
End Date:	March 17, 2021
Contact:	Pfizer CT.gov Call Center
Email:	ClinicalTrials.gov_Inquiries@pfizer.com
Phone:	1-800-718-1021

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO

This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an
extension period. The study will have a maximum duration of approximately 60 weeks. This
includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week
extension period and a 8 week Follow up Period.

Inclusion Criteria:

- Male or female subjects between 18-65 years of age, inclusive, at time of informed
consent.

- Must have moderate to severe active non-segmental vitiligo.

Exclusion Criteria:

- History of human immunodeficiency virus (HIV) or positive HIV serology at screening,

- Infected with hepatitis B or hepatitis C viruses.

- Have evidence of active or latent or inadequately treated infection with Mycobacterium
tuberculosis (TB)

We found this trial at

sites

University of Texas Southwestern Medical Center

1801 Inwood Rd
Dallas, Texas 75390

(214) 645-3300